Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-ILT3 CAR-T for R/R AML (M4/M5)
NCT04803929Phase 1Recruiting
- Sponsor
- Zhejiang Carbiogene Therapeutics Co. Ltd
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Anti-ILT3 CAR-T in acute myeloid leukemia (AML), sponsored by Zhejiang Carbiogene Therapeutics Co. Ltd. Primary endpoints: Rate of grade 3 or 4 treatment related adverse effects at 24 weeks and Implantation endpoint at 2 years. Started Mar 2021; status: recruiting.
02
Drugs
Anti-ILT3 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04803929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803929.